Select Page
Event info
Date:24 Nov
Time:12.30 - 16.30
Venue:Skåne University Hospital, Lund, Sweden

MVA R&D Network meeting – Emerging Cell and Gene Therapies

Medicon Valley Alliance together with Lund Stem Cell Center, Lund University have the pleasure to invite you the Medicon Valley Alliance R&D Network meeting on 24th of November, 2021 in Lund.

Cell and gene therapies are being widely accepted as one of the most transformative innovative trends in biopharmaceuticals. Cell and gene therapies are expected to increasingly shape the medical treatment and diagnosis across a wide range of diseases. Currently there are only a few approved cell and gene therapies on the market which shows that we are still in the early stages of clinical use of these treatments. The global cell and gene therapy market was valued at $4.4 billion in 2020 and is expected to reach $15.5 billion in 2025.

Despite the clinical, and commercial, potential in cell-based therapies the whole process from concept to commercialisation is a very demanding and challenging with a constant need for technological improvements, managing supply chain and manufacturing operations, regulatory concerns and enabling patient access.

In this MVA R&D Network meeting, hosted by Lund Stem Cell Center, leading researchers and industry players from the region will share their latest findings as well as discussing opportunities and challenges in developing ground-breaking cell and gene therapies.

Date: Wednesday 24th of November, 2021
Time: 12.30 – 16.30
Venue: Aulan (Auditorium), Skåne University Hospital Lund, Entrégatan 7, Lund, Sweden
Host: Lund Stem Cell Center
Moderator: Johan Flygare, Associate Professor, Lund Stem Cell Center



12.30 – 13.00 Arrival and registration
13.00 – 13.10 Welcome and introduction
Anette Steenberg, CEO, Medicon Valley Alliance
Johan Flygare, Associate Professor, Lund Stem Cell Center
13.10 – 13.15 How to patent stem cells
Peter Holm, Partner, European Patent Attorney, HØIBERG
13.15 – 13.30 Introduction to cell and gene Therapies and the hospital perspective 
Stefan Jovinge, Research Director, Skåne University Hospitals, Region Skåne
13.30 – 13.45 New approaches to enhancing the production of human liver and pancreatic cells from pluripotent stem cells
Joshua M. Brickman, Professor & Interim Executive Director, Novo Nordisk Foundation Center for Stem Cell Biology – DanStem
13.45 – 14.00 Development of a cancer gene therapy based on cellular reprogramming
Filipe Pereira, Associate Professor, Lund University & Co – Founder of Asgard Therapeutics
14.00 – 14.15 Germline stem cell-based therapies for fertility preservation and restoration
Eva Hoffman, Professor, University of Copenhagen & Fertility restoration consortium
14.15 – 14.40 Break
14.40 – 14.55 Bringing a pluripotent cell product to clinical trial for Parkinson’s Disease
Malin Parmar, Professor, Lund University 
14.55 – 15.10 Cell Therapy R&D in Novo Nordisk – Industry perspective and challenges
Louise Winkel, Director, Cell Formulation & Delivery, Novo Nordisk
15.10 – 15.25 Amniotics – Perspective on ATMP manufacturing
Jan Talts, COO, Amniotics AB
15.25 – 15.40 Karolinska Cell Therapy Center – an Infrastructure for Translation of ATMPs Into the Clinic
Pontus Blomberg, Director Karolinska Cell Therapy Center
15.40 – 16.00 Panel discussion and Q&A
All speakers, moderated by Johan Flygare, Associate Professor, Lund Stem Cell Center
16.00 – 16.30 Networking

Registration ends on 19th of November.

The MVA R&D Network
The Medicon Valley Alliance R&D Network is a professional and social network for C-level R&D executives (CSOs, CMOs, VPs), university professors and PIs, and top-level managers in the hospital sector. The network focuses on sharing best practice and experiences, as well as discussing current challenges for industry-academia collaboration and the commercialization of R&D in the Medicon Valley region, such as how we can strengthen collaboration and knowledge-sharing between academia and industry to stimulate start-up, scale-up, commercialization and growth and wat is required to turn great science into successful innovations.

Joining the network is free of charge but is limited to Medicon Valley Alliance members. Non-member organizations and companies are welcome to attend one network event to evaluate the relevance in joining the network. For more information please contact Sofia Norås


Host Sponsor of the event


MVA R&D Network is managed by In collaboration with